Pembrolizumab
- Generic Name
- Pembrolizumab
- Brand Names
- Keytruda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1374853-91-4
- Unique Ingredient Identifier
- DPT0O3T46P
- Background
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
- Indication
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
- Associated Conditions
- Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
- Conditions
- Interventions
- First Posted Date
- 2015-02-13
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 82
- Registration Number
- NCT02362997
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 161
- Registration Number
- NCT02362035
- Locations
- 🇺🇸
Research Site, Yakima, Washington, United States
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Conventional Magnetic Resonance ImagingProcedure: Diffusion Tensor ImagingProcedure: Diffusion Weighted ImagingProcedure: Dynamic Contrast-enhanced MR PerfusionProcedure: Dynamic Susceptibility Contrast-Perfusion-Weighted ImagingProcedure: Magnetic Resonance Spectroscopic ImagingBiological: Pembrolizumab
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 110
- Registration Number
- NCT02359565
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
- Conditions
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 882
- Registration Number
- NCT02358031
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 78
- Registration Number
- NCT02351739
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸James Cancer Hospital, Columbus, Ohio, United States
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Nasser Hanna, M.D.
- Target Recruit Count
- 93
- Registration Number
- NCT02343952
- Locations
- 🇺🇸
Fort Wayne Oncology & Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02337686
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab +/- Bevacizumab for Recurrent GBM
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT02337491
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 370
- Registration Number
- NCT02332668
- Locations
- 🇺🇸
Call for Information (Investigational Site 0019), Aurora, Colorado, United States
🇺🇸Call for Information (Investigational Site 0026), Boston, Massachusetts, United States
🇺🇸Call for Information (Investigational Site 0031), New York, New York, United States
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 81
- Registration Number
- NCT02331251
- Locations
- 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Western Regional Medical Center, Goodyear, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.